Abstract
Novel alginate gel-core lipid nanocapsules (LNCs) consisting of hydrogel islets in an oil filled matrix and surrounded by a polymeric shell were prepared by hot homogenization and double emulsion method, for co-delivery of both hydrophilic (gemcitabine) and hydrophobic (paclitaxel) anticancer drugs. This system was prepared using a relatively simple and organic solvent-free method using only excipients that are approved by the FDA. The liquid oil matrix allowed the solubilization and encapsulation of hydrophobic drugs such as paclitaxel, whereas alginate hydrogel islets encapsulated hydrophilic drugs such as gemcitabine. Alginate gel-core LNCs were characterized with respect to particle size, polydispersity index (PDI), morphology, encapsulation efficiency, and in vitro release. Dual drug-loaded alginate gel-core LNCs had a particle size of 171.8 ± 4.1 nm and PDI of 0.201 ± 0.005, respectively, and showed core–shell type spherical morphology with a smooth surface. In addition, alginate gel core-LNCs underwent sustained release of both drugs. These results suggest that alginate gel core-LNCs may be used for co-delivery of hydrophilic (gemcitabine) and hydrophobic (paclitaxel) anticancer drugs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
